WO1991019474A1 - Transdermal administration of buprenorphine - Google Patents
Transdermal administration of buprenorphine Download PDFInfo
- Publication number
- WO1991019474A1 WO1991019474A1 PCT/US1991/004189 US9104189W WO9119474A1 WO 1991019474 A1 WO1991019474 A1 WO 1991019474A1 US 9104189 W US9104189 W US 9104189W WO 9119474 A1 WO9119474 A1 WO 9119474A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- buprenorphine
- skin
- individual
- laminated composite
- permeation enhancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Definitions
- transdermal buprenorphine delivery system which has a contact area with the patient's skin of from 10 to
- Poration enhancement or “permeation enhancement” as used herein relates to an increase in the permeability of skin to a buprenorphine pharmacologically active agent, i.e., so as to increase the rate at which buprenorphine permeates into, and through the skin.
- a “permeation enhancer” is a material which achieves permeation enhancement of buprenorphine.
- Carriers or “vehicles” as used herein refer to carrier materials without pharmacological activity which are suitable for administration with other
- the present invention involves the transdermal administration of buprenorphine. This mode of
- composite generally designated 10
- Acrylate copolymer materials are available commercially. For example, Monsanto Chemical Company distributes a family of vinyl acetate-acrylate copolymer resin
- PGML is normally a mixture of propylene glycol monolaurate, propylene glycol dilaurate and either propylene glycol or methyl laurate or both.
- propylene glycol monolaurate is intended. to encompass the pure compound as well as the mixture that is sold commercially.
- the enhancer may be composed of a mixture of said esters, by themselves or in combination, with one or both of the mentioned ethers.
- Other enhancers which may be employed to advantage include diethylene glycol monomethyl and monoethyl ethers, lauric acid, lauric alcohol, capric acid, oleic acid, glycerol oleate, and the like. In using some of these materials care must be taken to avoid irritation which may accompany these materials at high use levels.
- the flow-through diffusion cells have a
- Static Cells In some experiments, static, side-by-side diffusion cells were used. Skin sections were mounted carefully between the half-cells of the diffusion cell and fastened with a rigid clamp. The receiver compartment was filled with phosphate buffer of pH 6.0 (isotonic). The donor compartment was charged with a saturated solution of buprenorphine in an appropriate vehicle or enhancer. The diffusion cells were placed in an oven and the temperature of the diffusion cell
- buprenorphine HCl showed relatively higher penetration than the base form.
- the formulation containing 20% lauryl alcohol in propylene glycol gave the highest skin flux (21.3 ⁇ 6.7 microg/cm 2 /h).
- Capric acid appeared to be a better penetration enhancer than lauric acid, as shown in Table 5.
- the systems of these Examples are matrix-type monolithic (i.e., there is no rate controlling membrane laminated to a backing). The drug release is controlled by the monolith and the skin.
- Various polymer i.e., there is no rate controlling membrane laminated to a backing.
- the drug is uniformly mixed in these polymer mixtures and then cast. Solvent is then removed and a backing layer is affixed.
- the average skin flux of buprenorphine HCl from 5% buprenorphine HCl silicone 2675 and 5% buprenorphine HCl silicone 2920 was 0.06+0.01 and 0.09+0.02
- HCl was mixed with polyisobutylene (PIB) (1:5:1) solution in hexane (30% wt %) and rotated for 4 hours.
- the drugpolymer mixture was than cast on polyester film (#1022 release liner) with a 10 mil knife.
- the solvent in the mixture was evaporated in a 75°C oven for 1 hour.
- the resulting polymer film was laminated with another polyester film (#1022).
- the same procedure was used to prepare a 2% buprenorphine HCl-PIB (1:5:3) system.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI925727A FI925727A0 (en) | 1990-06-20 | 1992-12-16 | TRANSDERMAL DOSERING AV BURPRENORFIN |
NO92924926A NO924926L (en) | 1990-06-20 | 1992-12-18 | TRANSDERMAL ADMINISTRATION OF BUPRENORPHINE |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/540,908 US5069909A (en) | 1990-06-20 | 1990-06-20 | Transdermal administration of buprenorphine |
US540,908 | 1990-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991019474A1 true WO1991019474A1 (en) | 1991-12-26 |
Family
ID=24157413
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1991/004189 WO1991019474A1 (en) | 1990-06-20 | 1991-06-12 | Transdermal administration of buprenorphine |
Country Status (10)
Country | Link |
---|---|
US (1) | US5069909A (en) |
EP (1) | EP0535111A4 (en) |
JP (1) | JPH06501243A (en) |
AU (1) | AU646606B2 (en) |
CA (1) | CA2085126A1 (en) |
FI (1) | FI925727A0 (en) |
IE (1) | IE912108A1 (en) |
NZ (1) | NZ238587A (en) |
PT (1) | PT98051A (en) |
WO (1) | WO1991019474A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0680754A2 (en) * | 1994-05-06 | 1995-11-08 | Nitto Denko Corporation | Percutaneous absorption preparation containing Buprenorphine |
WO1996019975A1 (en) * | 1994-12-24 | 1996-07-04 | Lts Lohmann Therapie-Systeme Gmbh | Transdermal resorption of active substances from supercooled masses |
WO1999020244A2 (en) * | 1997-10-18 | 1999-04-29 | Lts Lohmann Therapie-Systeme Gmbh | Method for transdermal application of active substances at high, constant dosis |
WO2000041683A2 (en) * | 1999-01-14 | 2000-07-20 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system with self-adhesive matrix, containing organic acid addition salts of morphine- or morphinan-type alkaloids |
US6344211B1 (en) | 1994-12-24 | 2002-02-05 | Lts Lohmann Therapie-Systeme Gmbh | Transdermal absorption of active substances from subcooled melts |
EP2366388A1 (en) | 2010-03-17 | 2011-09-21 | Ratiopharm GmbH | Non-occlusive transdermal therapeutic system for administering buprenorphine |
DE102011076653A1 (en) | 2011-05-27 | 2012-11-29 | Acino Ag | Transdermal therapeutic system containing buprenorphine and an alpha hydroxy acid |
WO2015136253A1 (en) * | 2014-03-10 | 2015-09-17 | Indivior Uk Limited | Sustained-release buprenorphine solutions |
US9782402B2 (en) | 2010-06-08 | 2017-10-10 | Indivior Uk Limited | Injectable composition comprising buprenorphine |
US10172849B2 (en) | 2010-06-08 | 2019-01-08 | Indivior Uk Limited | Compositions comprising buprenorphine |
US10646484B2 (en) | 2017-06-16 | 2020-05-12 | Indivior Uk Limited | Methods to treat opioid use disorder |
US11000520B2 (en) | 2014-11-07 | 2021-05-11 | Indivior Uk Limited | Buprenorphine dosing regimens |
Families Citing this family (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5252334A (en) * | 1989-09-08 | 1993-10-12 | Cygnus Therapeutic Systems | Solid matrix system for transdermal drug delivery |
SE9003665D0 (en) * | 1990-11-16 | 1990-11-16 | Kabivitrum Ab | MORPHINE PRODRUGS |
WO1993014727A1 (en) * | 1992-01-31 | 1993-08-05 | Cygnus Therapeutic Systems | Transdermal administration of buprenorphine in the form of ion pair complexes |
EP0668759B1 (en) * | 1992-11-09 | 2003-05-28 | Neurogesx, Inc. | Transdermal delivery of ketorolac |
AU5551394A (en) * | 1992-11-09 | 1994-06-08 | Pharmetrix Corporation | Combined analgesic delivery methods for pain management |
US5883115A (en) * | 1992-11-09 | 1999-03-16 | Pharmetrix Division Technical Chemicals & Products, Inc. | Transdermal delivery of the eutomer of a chiral drug |
US5591767A (en) * | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US5362566A (en) * | 1993-03-04 | 1994-11-08 | Minnesota Mining And Manufacturing Company | Coating composition, granules coated with same, and method of reducing dust generation |
WO1994022432A1 (en) * | 1993-04-07 | 1994-10-13 | Rexham Industries Corp. | Method of coating microporous membranes and resulting products |
US5380760A (en) * | 1993-11-19 | 1995-01-10 | Minnesota Mining And Manufacturing Company | Transdermal prostaglandin composition |
US5962477A (en) * | 1994-04-12 | 1999-10-05 | Adolor Corporation | Screening methods for cytokine inhibitors |
US6190691B1 (en) | 1994-04-12 | 2001-02-20 | Adolor Corporation | Methods for treating inflammatory conditions |
US5580574A (en) * | 1994-04-28 | 1996-12-03 | Hoffmann-La Roche Inc. | Pharmaceutical composition for transdermal delivery |
US5552153A (en) * | 1994-04-28 | 1996-09-03 | Hoffman-La Roche Inc. | Pharmaceutical composition for transdermal delivery |
US5552406A (en) * | 1994-06-17 | 1996-09-03 | The Mclean Hospital Corporation | Method for treating pain and brain perfusion abnormalities using mixed opioid agonist-antagonists |
US5589480A (en) * | 1994-08-17 | 1996-12-31 | Elkhoury; George F. | Topical application of opioid analgesic drugs such as morphine |
US5866143A (en) * | 1995-03-24 | 1999-02-02 | El Khoury And Stein, Ltd. | Topical application of opioid drugs such as morphine for relief of itching and skin disease |
US5990179A (en) * | 1995-04-28 | 1999-11-23 | Alza Corporation | Composition and method of enhancing electrotransport agent delivery |
US5985316A (en) * | 1995-04-28 | 1999-11-16 | Alza Corporation | Composition and method of enhancing electrotransport agent delivery |
US6573282B1 (en) | 1995-09-12 | 2003-06-03 | Adolor Corporation | Peripherally active anti-hyperalgesic opiates |
US5849761A (en) | 1995-09-12 | 1998-12-15 | Regents Of The University Of California | Peripherally active anti-hyperalgesic opiates |
US5667799A (en) * | 1995-10-30 | 1997-09-16 | Caldwell; Larry J. | Method for treating headache pain with topical local anesthetic compositions |
US5733571A (en) * | 1995-12-08 | 1998-03-31 | Euro-Celtique, S.A. | Transdermal patch for comparative evaluations |
JPH1036265A (en) * | 1996-07-19 | 1998-02-10 | Nitto Denko Corp | Buprenorphine percutaneous absorption preparation |
US5968547A (en) * | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
US5919473A (en) * | 1997-05-12 | 1999-07-06 | Elkhoury; George F. | Methods and devices for delivering opioid analgesics to wounds via a subdermal implant |
US6143278A (en) * | 1998-02-23 | 2000-11-07 | Elkhoury; George F. | Topical application of opioid analgesic drugs such as morphine |
US6011022A (en) * | 1998-03-03 | 2000-01-04 | El Khoury; George F. | Topical application of muscarinic analgesic drugs such as neostigmine |
US6103771A (en) * | 1998-03-20 | 2000-08-15 | Caldwell Galer Incorporated | Method of treating neuroma pain |
DE19814084B4 (en) * | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2 agonist-containing transdermal therapeutic system for the treatment of Parkinson's syndrome and process for its preparation |
US5994330A (en) * | 1998-11-09 | 1999-11-30 | El Khoury; Georges F. | Topical application of muscarinic agents such as neostigmine for treatment of acne and other inflammatory conditions |
KR100383252B1 (en) * | 1998-12-17 | 2003-07-16 | 주식회사 삼양사 | Transdermal Dosage Compositions Containing Buprenoline and Patches Comprising the Same |
DE60135441D1 (en) | 2000-02-08 | 2008-10-02 | Euro Celtique Sa | COMPOSITIONS WITH CONTROLLED RELEASE CONTAINING AN OPIOID AGONIST AND ANTAGONIST |
DE10041478A1 (en) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | New pharmaceutical composition |
US20020119187A1 (en) * | 2000-09-29 | 2002-08-29 | Cantor Adam S. | Composition for the transdermal delivery of fentanyl |
US20050208117A1 (en) * | 2001-03-16 | 2005-09-22 | Venkatraman Subramanian S | Transdermal administration of fentanyl and analogs thereof |
NZ528148A (en) * | 2001-03-16 | 2006-02-24 | Alza Corp | Transdermal patch for administering fentanyl |
WO2003032983A1 (en) * | 2001-06-05 | 2003-04-24 | Ronald Aung-Din | Transdermal migraine therapy |
US8329734B2 (en) | 2009-07-27 | 2012-12-11 | Afgin Pharma Llc | Topical therapy for migraine |
US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
DE10141650C1 (en) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate |
ATE394097T1 (en) * | 2002-03-20 | 2008-05-15 | Euro Celtique Sa | METHOD OF ADMINISTRATION OF BUPRENORPHINE FOR THE TREATMENT OF DEPRESSION |
DK2561860T3 (en) * | 2002-05-31 | 2018-04-30 | Titan Pharmaceuticals Inc | Implantable polymer device for prolonged release of buprenorphine |
EP2298302A1 (en) | 2002-06-10 | 2011-03-23 | Euro-Celtique S.A. | Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein |
US7771707B2 (en) | 2004-06-12 | 2010-08-10 | Collegium Pharmaceutical, Inc. | Abuse-deterrent drug formulations |
US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
US8246980B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
US8246979B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
DE10234673B4 (en) * | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Hot-melt TTS for the administration of rotigotine and process for its preparation, and use of rotigotine in the manufacture of a hot-melt TTS |
EP1530469B1 (en) * | 2002-08-20 | 2009-02-25 | Euro-Celtique S.A. | Transdermal dosage form comprising an active agent and a salt and free-base form of an antagonist |
ATE444296T1 (en) * | 2002-10-25 | 2009-10-15 | Euro Celtique Sa | ANALOGUE AND PRODRUGS OF BUPRENORPHINE |
ATE295726T1 (en) * | 2002-12-02 | 2005-06-15 | Sanol Arznei Schwarz Gmbh | ADMINISTRATION OF ROTIGOTINE FOR THE TREATMENT OF PARKINSON'S DISEASE BY IONTOPHORESIS |
EP1913938A1 (en) | 2002-12-13 | 2008-04-23 | Euro-Celtique S.A. | Transdermal buprenorphine dosage regimen for analgesia |
JP5054893B2 (en) * | 2002-12-13 | 2012-10-24 | ユーロ−セルティーク エス.エイ. | Transdermal buprenorphine for analgesia |
AU2003297074A1 (en) * | 2002-12-13 | 2004-07-09 | Euro-Celtique S.A. | Transdermal buprenorphine to treat pain in sickle cell crisis |
DE10261696A1 (en) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Device for the transdermal administration of rotigotine base |
NZ542548A (en) | 2003-03-31 | 2009-04-30 | Titan Pharmaceuticals Inc | Implantable polymeric device for sustained release of dopamine agonist |
EP1644004A4 (en) | 2003-06-20 | 2010-10-06 | Ronald Aung-Din | Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions |
MXPA06000990A (en) * | 2003-07-25 | 2006-04-11 | Euro Celtique Sa | Preoperative treatment of post operative pain. |
US20080020028A1 (en) * | 2003-08-20 | 2008-01-24 | Euro-Celtique S.A. | Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent |
WO2005081825A2 (en) | 2004-02-23 | 2005-09-09 | Euro-Celtique S.A. | Abuse resistance opioid transdermal delivery device |
US20060078604A1 (en) * | 2004-10-08 | 2006-04-13 | Noven Pharmaceuticals, Inc. | Transdermal drug delivery device including an occlusive backing |
FR2879931B1 (en) * | 2004-12-24 | 2007-03-30 | Rhodia Chimie Sa | SILICONE MATERIAL FOR THE RELEASE OF AN ACTIVE MOLECULE |
US20060223786A1 (en) * | 2005-04-01 | 2006-10-05 | Smith David J | Transdermal pain control method and device |
TWI366460B (en) | 2005-06-16 | 2012-06-21 | Euro Celtique Sa | Cannabinoid active pharmaceutical ingredient for improved dosage forms |
US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
BRPI0618891A2 (en) * | 2005-11-21 | 2011-09-13 | Schering Plough Ltd | pharmaceutical compositions |
US8518926B2 (en) | 2006-04-10 | 2013-08-27 | Knopp Neurosciences, Inc. | Compositions and methods of using (R)-pramipexole |
US20070248657A1 (en) * | 2006-04-25 | 2007-10-25 | Smith David J | Multi-compartment transdermal pain control device |
CN101448498B (en) | 2006-05-16 | 2011-04-27 | 诺普神经科学股份有限公司 | Compositions of r(+) and s(-) pramipexole and methods of using the same |
EP2089010A1 (en) | 2006-10-24 | 2009-08-19 | The John Hopkins University | Rapid release mini-tablets provide analgesia in laboratory animals |
AU2007325918B2 (en) | 2006-11-03 | 2013-10-17 | Durect Corporation | Transdermal delivery systems comprising bupivacaine |
US8524695B2 (en) | 2006-12-14 | 2013-09-03 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
CA2681110A1 (en) | 2007-03-14 | 2008-09-18 | Knopp Neurosciences, Inc. | Synthesis of chirally purified substituted benzothiazole diamines |
WO2008153611A2 (en) | 2007-05-25 | 2008-12-18 | Qlt Usa, Inc. | Sustained delivery formulations of risperidone compounds |
JP5687901B2 (en) * | 2007-10-15 | 2015-03-25 | アルザ・コーポレーシヨン | Transdermal administration of fentanyl by replacement once a day |
CA2729346A1 (en) | 2008-06-30 | 2010-01-14 | Afgin Pharma, Llc | Topical regional neuro-affective therapy |
CA2734491A1 (en) | 2008-08-19 | 2010-02-25 | Knopp Neurosciences, Inc. | Compositions and methods of using (r)-pramipexole |
US20100221313A1 (en) * | 2008-12-01 | 2010-09-02 | Innovative Pharmaceuticals, Llc | Transdermal reservoir patch |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
CA2796575C (en) | 2010-04-13 | 2018-05-15 | Relmada Therapeutics, Inc. | Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use |
KR101572336B1 (en) | 2010-12-22 | 2015-11-26 | 퍼듀 퍼머 엘피 | Encased tamper resistant controlled release dosage forms |
CN103327969A (en) | 2010-12-23 | 2013-09-25 | 普渡制药公司 | Tamper resistant solid oral dosage forms |
PE20141198A1 (en) | 2011-09-19 | 2014-10-05 | Orexo Ab | NEW PHARMACEUTICAL COMPOSITION RESISTANT TO ABUSE FOR THE TREATMENT OF OPIOID DEPENDENCE |
SG10201604754VA (en) | 2011-12-12 | 2016-08-30 | Lohmann Therapie Syst Lts | Transdermal delivery system comprising buprenorphine |
US9512096B2 (en) | 2011-12-22 | 2016-12-06 | Knopp Biosciences, LLP | Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
EP2938391B1 (en) | 2012-12-28 | 2022-07-27 | Teikoku Seiyaku Co., Ltd. | Extended buprenorphine transdermal delivery compositions |
EA201500742A1 (en) | 2013-02-05 | 2015-12-30 | Пердью Фарма Л.П. | PHARMACEUTICAL COMPOSITIONS PROTECTED FROM NON-GOAL USE |
US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
ES2599802T3 (en) | 2013-06-04 | 2017-02-03 | Lts Lohmann Therapie-Systeme Ag | Transdermal Administration System |
CA2918035C (en) | 2013-07-12 | 2023-01-03 | Knopp Biosciences Llc | Use of dexpramipexole in the treatment of disorders associated with elevated levels of eosinophils and/or basophils |
US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
AU2014306683B2 (en) | 2013-08-13 | 2017-10-12 | Knopp Biosciences Llc | Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders |
ES2871556T3 (en) | 2013-08-13 | 2021-10-29 | Knopp Biosciences Llc | Compositions and methods for the treatment of chronic urticaria |
DE102014013448A1 (en) | 2014-09-16 | 2016-03-17 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermal therapeutic system comprising buprenorphine |
US9656441B2 (en) | 2015-01-08 | 2017-05-23 | Alfred E. Tiefenbacher ( Gmbh & Co. Kg) | Transdermal patch |
US10383816B2 (en) | 2015-03-02 | 2019-08-20 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with cannabinoid combination products |
JP2018507262A (en) | 2015-03-02 | 2018-03-15 | アフギン ファーマ, エルエルシーAfgin Pharma, Llc | Localized local nerve action therapy using cannabinoids |
JP2018526415A (en) * | 2015-09-14 | 2018-09-13 | アムニール ファーマシューティカルズ エルエルシー | Transdermal delivery system |
US9737530B1 (en) | 2016-06-23 | 2017-08-22 | Collegium Pharmaceutical, Inc. | Process of making stable abuse-deterrent oral formulations |
US20180049994A1 (en) | 2016-08-16 | 2018-02-22 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with caryophyllene |
EP3518896A4 (en) | 2016-09-29 | 2020-08-05 | Gesea Biosciences Inc. | Bioerodible implant for long-term drug delivery and associated methods of manufacture and use |
CN113811950A (en) * | 2018-12-14 | 2021-12-17 | 派尔疗法股份有限公司 | Digital therapeutic assembly for optimizing the induction of buprenorphine-containing products |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4806341A (en) * | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3474101A (en) * | 1960-09-05 | 1969-10-21 | Reckitt & Sons Ltd | Thebaine and oripavine derivatives |
US3734097A (en) * | 1969-04-01 | 1973-05-22 | Alza Corp | Therapeutic adhesive tape |
GB8332556D0 (en) * | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
US4626539A (en) * | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
AU601528B2 (en) * | 1986-12-22 | 1990-09-13 | Ortho-Mcneil Pharmaceutical, Inc. | Resilient transdermal drug-delivery device and compositions and devices employing fatty acid esters/ethers of alkanediols and percutaneous absorption enhancers |
EP0282156B1 (en) * | 1987-03-09 | 1991-04-17 | Alza Corporation | Composition for the prevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug |
WO1988009676A1 (en) * | 1987-06-01 | 1988-12-15 | Warner-Lambert Company | Fatty acids and their small chain esters as penetration enhancers in aqueous systems |
US4956171A (en) * | 1989-07-21 | 1990-09-11 | Paco Pharmaceutical Services, Inc. | Transdermal drug delivery using a dual permeation enhancer and method of performing the same |
DE3939376C1 (en) * | 1989-11-29 | 1991-05-08 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De | |
KR950005865B1 (en) * | 1990-04-23 | 1995-06-02 | 데이진 가부시끼가이샤 | Plaster |
-
1990
- 1990-06-20 US US07/540,908 patent/US5069909A/en not_active Expired - Lifetime
-
1991
- 1991-06-12 EP EP19910911974 patent/EP0535111A4/en not_active Withdrawn
- 1991-06-12 CA CA002085126A patent/CA2085126A1/en not_active Abandoned
- 1991-06-12 AU AU80722/91A patent/AU646606B2/en not_active Ceased
- 1991-06-12 WO PCT/US1991/004189 patent/WO1991019474A1/en not_active Application Discontinuation
- 1991-06-12 JP JP3511267A patent/JPH06501243A/en active Pending
- 1991-06-18 NZ NZ238587A patent/NZ238587A/en unknown
- 1991-06-19 IE IE210891A patent/IE912108A1/en not_active Application Discontinuation
- 1991-06-20 PT PT98051A patent/PT98051A/en not_active Application Discontinuation
-
1992
- 1992-12-16 FI FI925727A patent/FI925727A0/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4806341A (en) * | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0680754A2 (en) * | 1994-05-06 | 1995-11-08 | Nitto Denko Corporation | Percutaneous absorption preparation containing Buprenorphine |
EP0680754A3 (en) * | 1994-05-06 | 1996-03-06 | Nitto Denko Corp | Percutaneous absorption preparation containing Buprenorphine. |
US5618555A (en) * | 1994-05-06 | 1997-04-08 | Itto Denko Corporation | Percutaneous absorption preparation |
WO1996019975A1 (en) * | 1994-12-24 | 1996-07-04 | Lts Lohmann Therapie-Systeme Gmbh | Transdermal resorption of active substances from supercooled masses |
US6344211B1 (en) | 1994-12-24 | 2002-02-05 | Lts Lohmann Therapie-Systeme Gmbh | Transdermal absorption of active substances from subcooled melts |
WO1999020244A2 (en) * | 1997-10-18 | 1999-04-29 | Lts Lohmann Therapie-Systeme Gmbh | Method for transdermal application of active substances at high, constant dosis |
WO1999020244A3 (en) * | 1997-10-18 | 1999-07-01 | Lohmann Therapie Syst Lts | Method for transdermal application of active substances at high, constant dosis |
US6280766B1 (en) | 1997-10-18 | 2001-08-28 | Lts Lehman Therapie-Systeme Gmbh | Method for transdermal application of active substances at high constant dosage |
WO2000041683A2 (en) * | 1999-01-14 | 2000-07-20 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system with self-adhesive matrix, containing organic acid addition salts of morphine- or morphinan-type alkaloids |
WO2000041683A3 (en) * | 1999-01-14 | 2001-11-08 | Lohmann Therapie Syst Lts | Transdermal therapeutic system with self-adhesive matrix, containing organic acid addition salts of morphine- or morphinan-type alkaloids |
EP2366388A1 (en) | 2010-03-17 | 2011-09-21 | Ratiopharm GmbH | Non-occlusive transdermal therapeutic system for administering buprenorphine |
US10198218B2 (en) | 2010-06-08 | 2019-02-05 | Indivior Uk Limited | Injectable flowable composition comprising buprenorphine |
US10592168B1 (en) | 2010-06-08 | 2020-03-17 | Indivior Uk Limited | Injectable flowable composition comprising buprenorphine |
US10558394B2 (en) | 2010-06-08 | 2020-02-11 | Indivior Uk Limited | Injectable flowable composition comprising buprenorphine |
US9782402B2 (en) | 2010-06-08 | 2017-10-10 | Indivior Uk Limited | Injectable composition comprising buprenorphine |
US9827241B2 (en) | 2010-06-08 | 2017-11-28 | Indivior Uk Limited | Injectable flowable composition comprising buprenorphine |
US10172849B2 (en) | 2010-06-08 | 2019-01-08 | Indivior Uk Limited | Compositions comprising buprenorphine |
DE102011076653A1 (en) | 2011-05-27 | 2012-11-29 | Acino Ag | Transdermal therapeutic system containing buprenorphine and an alpha hydroxy acid |
WO2012163665A1 (en) | 2011-05-27 | 2012-12-06 | Acino Ag | Transdermal therapeutic system comprising buprenorphine and an alpha-hydroxy acid |
US10022367B2 (en) | 2014-03-10 | 2018-07-17 | Indivior Uk Limited | Sustained-release buprenorphine solutions |
US10517864B2 (en) | 2014-03-10 | 2019-12-31 | Indivior Uk Limited | Sustained-release buprenorphine solutions |
WO2015136253A1 (en) * | 2014-03-10 | 2015-09-17 | Indivior Uk Limited | Sustained-release buprenorphine solutions |
US11000520B2 (en) | 2014-11-07 | 2021-05-11 | Indivior Uk Limited | Buprenorphine dosing regimens |
US11839611B2 (en) | 2014-11-07 | 2023-12-12 | Indivior Uk Limited | Buprenorphine dosing regimens |
US10646484B2 (en) | 2017-06-16 | 2020-05-12 | Indivior Uk Limited | Methods to treat opioid use disorder |
Also Published As
Publication number | Publication date |
---|---|
JPH06501243A (en) | 1994-02-10 |
EP0535111A1 (en) | 1993-04-07 |
FI925727A (en) | 1992-12-16 |
US5069909A (en) | 1991-12-03 |
FI925727A0 (en) | 1992-12-16 |
AU646606B2 (en) | 1994-02-24 |
PT98051A (en) | 1992-04-30 |
AU8072291A (en) | 1992-01-07 |
EP0535111A4 (en) | 1993-10-20 |
NZ238587A (en) | 1994-06-27 |
IE912108A1 (en) | 1992-01-01 |
CA2085126A1 (en) | 1991-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5069909A (en) | Transdermal administration of buprenorphine | |
AU633500B2 (en) | Laminated composite for transdermal administration of fentanyl | |
US5591767A (en) | Liquid reservoir transdermal patch for the administration of ketorolac | |
US5202125A (en) | Method and systems for administering nitroglycerin transdermally at enhanced transdermal fluxes | |
US4789547A (en) | Transdermal matrix system | |
US5186939A (en) | Laminated composite for transdermal administration of fentanyl | |
US20070264319A1 (en) | Transdermal Antiemesis Delivery System, Method and Composition Therefor | |
KR20010036685A (en) | Transdermal fentanyl delivery matrix system | |
US4910205A (en) | Transdermal delivery of loratadine | |
EP1503743B1 (en) | Transdermal delivery system with two superimposed adhesive layers having different affinities to the active substance comprised | |
Roy et al. | Transdermal delivery of buprenorphine through cadaver skin | |
JPH0684304B2 (en) | Transdermal system for timolol | |
KR100383252B1 (en) | Transdermal Dosage Compositions Containing Buprenoline and Patches Comprising the Same | |
ZA200506056B (en) | Formulation and methods for the treatment of thrombocythemia | |
NZ244064A (en) | Transdermal formulation for administering prazosin including a skin permeation enhancer mixture | |
JPH0667835B2 (en) | Pharmaceutical composition | |
EP1028682A1 (en) | Transdermal propentofylline compositions for the treatment of alzheimer's disease | |
WO1993014727A1 (en) | Transdermal administration of buprenorphine in the form of ion pair complexes | |
US20050232983A1 (en) | Transdermal patch | |
WO1994009777A1 (en) | Transdermal delivery of ketorolac |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA FI JP NO |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2085126 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 925727 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991911974 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1991911974 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1991911974 Country of ref document: EP |